Karyopharm Therapeutics Inc. — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
10-Q/A
144
3
4
4/A
424B3
424B4
424B5
5
8-A12B
8-K
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
DRSLTR
EFFECT
POS AM
POSASR
PRE 14A
RW
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-I
SC TO-I/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001503802-26-000011 | Mar 27, 2026 | — |
| 8-K | 8-K | 0001193125-26-120770 | Mar 24, 2026 | — |
| 4 | 4 | 0001837741-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 4 | 4 | 0002045943-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001825322-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001804460-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001865796-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 4 | 4 | 0001942597-26-000003 | Mar 3, 2026 | Mar 2, 2026 |
| 8-K | 8-K | 0001503802-26-000006 | Mar 3, 2026 | Feb 27, 2026 |
| 8-K | 8-K | 0001193125-26-059349 | Feb 19, 2026 | Feb 18, 2026 |
| 4 | 4 | 0001193125-26-059332 | Feb 19, 2026 | Feb 17, 2026 |
| SCHEDULE 13G/A | — | 0001897612-26-000267 | Feb 17, 2026 | — |
| 10-K | 10-K | 0001193125-26-049397 | Feb 13, 2026 | Dec 31, 2025 |
| 8-K | 8-K | 0001193125-26-047670 | Feb 12, 2026 | — |
| SCHEDULE 13G/A | — | 0000902664-26-000896 | Feb 12, 2026 | — |
| SCHEDULE 13G | — | 0001104659-26-012689 | Feb 10, 2026 | — |
| 4 | 4 | 0001193125-26-042799 | Feb 9, 2026 | Feb 5, 2026 |
| 4 | 4 | 0001193125-26-037584 | Feb 4, 2026 | Feb 3, 2026 |
| 4 | 4 | 0001193125-26-035687 | Feb 3, 2026 | Jan 31, 2026 |
| 4 | 4 | 0001193125-26-035661 | Feb 3, 2026 | Jan 31, 2026 |
| 4 | 4 | 0001193125-26-035655 | Feb 3, 2026 | Jan 31, 2026 |
| 4 | 4 | 0001193125-26-035663 | Feb 3, 2026 | Jan 31, 2026 |
| 4 | 4 | 0001193125-26-035682 | Feb 3, 2026 | Jan 31, 2026 |
| 4 | 4 | 0001193125-26-029599 | Jan 29, 2026 | Jan 27, 2026 |
| SCHEDULE 13G/A | — | 0001315863-26-000103 | Jan 29, 2026 | — |
| 4 | 4 | 0001193125-26-019428 | Jan 22, 2026 | Jan 21, 2026 |
| 8-K | 8-K | 0001193125-26-009738 | Jan 12, 2026 | — |
| DEF 14A | DEF 14A | 0001193125-26-008939 | Jan 9, 2026 | Feb 18, 2026 |
| PRE 14A | PRE 14A | 0001193125-25-337113 | Dec 30, 2025 | — |
| 424B3 | 424B3 | 0001193125-25-291930 | Nov 24, 2025 | — |
| 424B3 | 424B3 | 0001193125-25-291933 | Nov 24, 2025 | — |
| SCHEDULE 13G/A | — | 0000902664-25-004954 | Nov 14, 2025 | — |
| SCHEDULE 13G/A | — | 0001897612-25-000507 | Nov 7, 2025 | — |
| SCHEDULE 13G/A | — | 0001493152-25-020601 | Nov 3, 2025 | — |
| 8-K | 8-K | 0001193125-25-261663 | Nov 3, 2025 | — |
| 10-Q | 10-Q | 0001193125-25-261667 | Nov 3, 2025 | Sep 30, 2025 |
| S-3 | S-3 | 0001193125-25-262571 | Nov 3, 2025 | — |
| S-3 | S-3 | 0001193125-25-262581 | Nov 3, 2025 | — |
| SCHEDULE 13G/A | — | 0000102909-25-000154 | Oct 30, 2025 | — |
| SCHEDULE 13G | — | 0001493152-25-018449 | Oct 17, 2025 | — |
| 4 | 4 | 0001193125-25-241471 | Oct 16, 2025 | Oct 15, 2025 |
| 4 | 4 | 0001193125-25-241468 | Oct 16, 2025 | Oct 15, 2025 |
| 4 | 4 | 0001193125-25-241479 | Oct 16, 2025 | Oct 15, 2025 |
| 4 | 4 | 0001193125-25-241484 | Oct 16, 2025 | Oct 15, 2025 |
| 4 | 4 | 0001193125-25-241487 | Oct 16, 2025 | Oct 15, 2025 |
| 4 | 4 | 0001193125-25-241461 | Oct 16, 2025 | Oct 15, 2025 |
| 8-K | 8-K | 0001193125-25-239015 | Oct 14, 2025 | Oct 10, 2025 |
| 8-K | 8-K | 0001193125-25-233983 | Oct 8, 2025 | Oct 7, 2025 |
| 4 | 4 | 0001193125-25-230359 | Oct 3, 2025 | Oct 1, 2025 |
| 4 | 4 | 0001193125-25-205052 | Sep 16, 2025 | Sep 12, 2025 |